|
Variable
|
n
|
Univariate analysis
|
Multivariate analysis
|
|---|
|
HR (95% CI)
|
P value
|
HR (95% CI)
|
P value
|
|---|
|
Gender
|
Male
|
61
|
1 (reference)
|
0.657
| | |
|
Female
|
12
|
0.807 (0.313–2.080)
| |
|
Age (y)
|
< 65
|
26
|
1 (reference)
|
0.422
| | |
|
≥ 65
|
47
|
1.340 (0.656–2.738)
| |
|
Performance status
|
0 or 1
|
57
|
1 (reference)
|
0.004 a
|
1 (reference)
|
0.066
|
|
2
|
16
|
2.975 (1.431–6.186)
|
2.051 (0.954–4.410)
|
|
Body surface area (m2)
|
< 1.50
|
30
|
1 (reference)
|
0.162
| | |
|
≥ 1.50
|
43
|
1.664 (0.815–3.398)
| |
|
eGFR (ml/min/1.73m2)
|
< 60
|
13
|
1 (reference)
|
0.838
| | |
|
≥ 60
|
60
|
1.096 (0.455–2.643)
| |
|
Tumor size (cm)
|
< 5
|
35
|
1 (reference)
|
< 0.001 a
|
1 (reference)
|
0.332
|
|
≥ 5
|
38
|
3.755 (1.784–7.903)
|
1.638 (0.605–4.436)
|
|
Post-dCRT chemotherapy
|
–
|
17
|
1 (reference)
|
0.646
| | |
|
+
|
56
|
0.823 (0.358–1.891)
| |
|
Histological type
|
Differentiated
|
64
|
1 (reference)
|
0.876
| | |
|
Un-differentiated
|
9
|
1.079 (0.418–2.782)
| |
|
Clinical stage in UICC 8th edition
|
I (cT1b) - III
|
38
|
1 (reference)
|
< 0.001 a
|
1 (reference)
|
0.006 a
|
|
IVA or IVB (cM1-lym)
|
35
|
5.177 (2.448–10.946)
|
4.085 (1.488–11.211)
|
|
Radiation dose (Gy)
|
< 57
|
13
|
1 (reference)
|
0.670
| | |
|
≥ 57
|
60
|
1.229 (0.477–3.169)
| |
|
Nedaplatin dose intensity in dCRT (%)
|
< 90
|
45
|
1 (reference)
|
0.360
| | |
|
≥ 90
|
28
|
0.716 (0.351–1.463)
| |
|
5-fluorouracil dose intensity in dCRT (%)
|
< 90
|
47
|
1 (reference)
|
0.130
| | |
|
≥ 90
|
26
|
0.556 (0.261–1.188)
| |
|
SLFN11 expression
|
Low (< 51)
|
37
|
1 (reference)
|
0.018 a
|
1 (reference)
|
0.001 a
|
|
(H-score)
|
High (≥ 51)
|
36
|
0.438 (0.221–0.866)
|
0.295 (0.143–0.605)
|
- Abbreviations: HR hazard ratio, CI confidence interval, eGFR estimated glomerular filtration rate, cM1-lym distant lymph node metastasis, dCRT definitive chemoradiotherapy, H-score histo-score
- astatistically significant
